5 Minutes Read
Shilpa Medicare’s unit 4 in Telangana gets European certification
KV Prasad Jun 13, 2022, 06:35 AM IST (Published)
Listen to the Article (6 Minutes)
Summary
The pharma company received the Good Manufacturing Practice (GMP) certification from AGES, Austria, for its unit 4 facility in Jadcherla, Telangana. Shares of Shilpa Medicare Ltd ended at ₹540.45, up by ₹31.25, or 6.14%, on the BSE.
Drug firm Shilpa Medicare Ltd on Tuesday (April 16) said it has received the Good Manufacturing Practice (GMP) certification from AGES, Austria, for its unit 4 facility in Jadcherla, Telangana.
“This is to inform you that Shilpa Medicare Limited, Unit 4, Jadcherla; Telangana, India was inspected by AGES, Austria from 22 January 2024 until 26 January 2024,” the company said in a stock exchange filing.
“Following a successful inspection, the Unit has been issued GMP Certification from Ages, Austria. The previous EU – GMP inspection for this facility was in January 2020,” it added.
Also Read: Jio Financial Services, BlackRock in 50:50 JV for wealth management, brokerage business
The unit, which was last inspected for EU-GMP compliance in January 2020, underwent a thorough evaluation of its manufacturing, testing, and distribution processes for sterile injections, as well as non-sterile tablets and capsule-finished dosage forms.
“This unit of Shilpa Medicare is engaged in the manufacture, testing and distribution of sterile Injections and non-sterile tablets and Capsule finished dosage forms in the US, Europe and rest of the world markets,” it said,
The inspection will facilitate the continued supply of medicines for commercial distribution to various countries of the European Union.
Also Read: Manappuram Finance plans fundraise of up to $500 million
Shares of Shilpa Medicare Ltd ended at ₹540.45, up by ₹31.25, or 6.14%, on the BSE.
Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout
3 Mins Read
Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter
Daily Newsletter
